BioRestorative Therapies, Inc. · NASDAQ:BRTX

BioRestorative Therapies — Investor Presentation (January 2024)

24 slides from BioRestorative Therapies's investor presentation, January 2024

  1. Slide 1: BioRestorative Therapies

    Rectorate therapies ——=pf Nasdaq of Nasdaq Company aN 40 Marcus Drive, Melville, 11747 NY 1 www.biorestorative.com

  2. Slide 2: Forward Looking Statement

    FORWARD LOOKING STATEMENT STATEMENTS IN THIS PRESENTATION, INCLUDING THE INFORMATION SET FORTH AS TO THE FUTURE FINANCIAL OR OPERATING PERFORMANCE OF BIORESTORATIVE THERAPIES, INC. (THE “COMPANY”) THAT ARE NOT CURRENT OR HISTORICAL FACTUAL STATEMENTS MAY CONSTITUTE “FORWARD LOOKING” INFORMATION WITH

  3. Slide 3: Leadership

    LEADERSHIP LANCE ALSTODT ROBERT KRISTAL FRANCISCO SILVA BOB PACCASASSI Chairman & CEO Chief Financial Officer Vice President of R&D Vice President of Quality Lance leads BRTX’s mission to Robert has a versatile Francisco has over 20 years of Robert has over 25 years of improve the lives of patients

  4. Slide 4: Fully Integrated Regenerative Medicine Company

    FULLY INTEGRATED REGENERATIVE MEDICINE COMPANY Preclinical Clinical Commercial BioCosmetics ThermoStem BRTX-100 Cell based Tech Bone Marrow Derived ECM, Exosomes, Brown Adipose Mesenchymal Stem Derived Stem Cells Growth Factors and Cells hPL 4

  5. Slide 5: Commercial Cosmetic Products

    BIORESTORATIVE THERAPIES INC-COMMERCIAL COSMETIC PRODUCTS Key Features of Cosmetics and Hair Growth Biologics Products • Global Cosmetic market $63 • cGMP ISO 7 Certified Facility • Umbilical cord derived billion and growing • Molecular Biology Expertise • Highly enriched & potent • Global injectabl

  6. Slide 6: Clinical / Preclinical Programs

    Clinical / Preclinical Programs Preclinical Phase 1 Phase 2 Phase 3 Spine • Lumbar Autologous • Cervical • Thoracic Musculoskeletal System • Hips/Knees • Extremities • Avascular Zones Metabolic • Type 2 Diabetes • Obesity Allogeneic • PCOS Brown Adipose Stem Cells • ARDS • Long Hauler Covid Gene Mod

  7. Slide 7: Chronic Lumbar Disc Disease Program – Phase 2

    CHRONIC LUMBAR DISC DISEASE PROGRAM – PHASE 2  Lead investigational therapeutic product  Autologous (patient’s own) cell-based biologic  Hypoxic (low oxygen) cultured, bone marrow-derived  Single intradiscal injection – anticipated 30 minute in-office procedure DISC/SPINE  Prior human data prov

  8. Slide 8: Market Opportunity – BRTX-100

    MARKET OPPORTUNITY – BRTX 100 258 MILLION American adult population 64.5 MILLION American adults with chronic lower back pain prevalence 32 MILLION American adults with diagnosed and treated disc degeneration 15 MILLION Americans have pain caused by a protruding or injured disc 2.5 MILLION Invasive

  9. Slide 9: Standard of Care: Clinical and Economic Problem

    STANDARD OF CARE: CLINICAL AND ECONOMIC PROBLEM CONSERVATIVE TREATMENTS SURGICAL TREATMENTS OFTEN RECURRENT WITH RE-OP RATES OFTEN 10-20% ORAL MEDICATION TREATMENT/OPIOIDS SIMPLE ELEGANT SOLUTION SPINAL FUSION SURGERY INTRODUCE HYPOXIC CULTURED $1,000 - $2,000 Annually AUTOLOGOUS MSCs $110,000 1, 5

  10. Slide 10: Logistical/Clinical Process

    LOGISTICAL/CLINICAL PROCESS Shipping 3 Shipping 1 Cryoport 5 Cryoport . Intradiscal delivery Bone marrow and BRTX-100® blood collected from Manufactured & of BRTX-100® subject QC released Sample shipped at BRTX-100® shipped ambient to frozen to clinical BioRestorative site Therapies Clinical Site 2

  11. Slide 11: Cleared DSMB June 2023

    CLEARED DSMB June 2023 • Unanimous approval by the DSMB to continue trial without changes • BRTX-100 is safe and well tolerated • All 4 subjects successfully dosed with either 40 mil hMSCs or placebo • First time 40 million cells injected in a human subject • 3:1 randomization • No Significant Adver

  12. Slide 12: Positive Human Data

    POSITIVE HUMAN DATA Human data from studies of therapies similar to brtx-100 show reduced pain, increased function, and an absence of significant safety issues with a durable response. 12

  13. Slide 13: Trial Design

    TRIAL DESIGN FDA Cleared IND 17275: Phase 2 Randomized, Controlled Study Design in Patients with CLDD Study Design and Patient Population  Study includes 99 subjects (2:1 product to placebo)  40.000.000 cells/dose  Included subjects will have only one symptomatic diseased disc  Primary efficacy

  14. Slide 14: Competitive Landscape Key Differentiating Factors

    COMPETITIVE LANDSCAPE KEY DIFFERENTIATING FACTORS KEY ATTRIBUTES BRTX-100 ADVANTAGES: Normoxic cultured –  Autologous cells means low to no risk of rejection, Hypoxic cultured – in low with normal oxygen greater safety profile (introduction of viral/genetic), oxygen environment (5%) environment (~2

  15. Slide 15: BioRestorative Therapy Programs

    BIORESTORATIVE THERAPY PROGRAMS Metabolic Program ThermoStem Program  “Off the shelf” allogeneic cell-based therapy targeted to treat obesity, Type 2 diabetes and metabolic disorders using brown fat  stem cells  Brown fat has been shown to regulate metabolic homeostasis in the body  Large librar

  16. Slide 16: Metabolic Program Highlights

    METABOLIC PROGRAM HIGHLIGHTS • First human stem cell derived BAT transfer White Fat • Creation of first human 3D engineered artificial brown adipose tissue construct (aBAT) • Successful delivery of 3D aBAT construct in mouse model Beige Fat • Transplantation of aBAT lowered blood glucose levels • Tr

  17. Slide 17: Metabolic Program Clinical Pathway

    METABOLIC PROGRAM CLINICAL PATHWAY • Expect filing a Drug Master File (“DMF”) with the FDA to facilitate licensing opportunities around Thermostem • Scheduling Pre-IND (Investigational New Drug) meeting with FDA to discuss first-in-man fast-track regulatory pathways • Upon FDA approval commence Phas

  18. Slide 18: Intellectual Property

    INTELLECTUAL PROPERTY PROGRAM: PROGRAM: DISC/SPINE METABOLIC (THERMOSTEM) PATENT TITLES PATENT TITLES • Methods and Compositions to facilitate repair • Brown Fat Compositions and Methods of avascular tissue • Human Brown Adipose Derived Stem Cells and Uses • Surgical Methods and Compositions to • No

  19. Slide 19: 2023 Accomplishments

    2023 ACCOMPLISHMENTS  Expanded Thermostem patent portfolio in US and Japan  Two Notice of Allowances  Completed 4 patient Safety Run-in component for Phase 2  Announced a filing and execution of an ATM  Announced Northwell Healthcare Partnership – Largest Healthcare System in the Northeast  Cl

  20. Slide 20: Scientific Advisory Board

    SCIENTIFIC ADVISORY BOARD Dr. Marasco, is a principal faculty member of Harvard Stem Cell Institute as well as a Professor in the Department WAYNE MARASCO, MD, PhD of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Chairman of SAB Medical School. J

  21. Slide 21: Company Highlights

    COMPANY HIGHLIGHTS  cGMP ISO-7 Certified Clean room  Disruptive Platform Technologies in Cellular Therapy  Strong Preliminary Data Indicative of Positive Trial Outcomes  Active Phase 2 Trial in Spine  Addressing Multi-Billion Dollar Markets with Unmet Needs  Opportunity for Key Strategic Partn

  22. Slide 22: Financial Summary

    FINANCIAL SUMMARY Current Capitalization Shares Basic Shares Outstanding 4,706,000 Cash 12.2 MILLION Debt $0 Data as Q3 filing 22

  23. Slide 23: BioRestorative Upcoming Milestones

    BIORESTORATIVE UPCOMING MILESTONES Platform Stage Situation Overview Skin regeneration, Tissue derived facial application • Regenerative Cosmetic & Aesthetic treatment to rejuvenate Exosome product /hair growth skin and grow hair Degenerative Disc BRTX-100 Disease (DDD) • Anticipate providing update

  24. Slide 24: Biorestorative Therapies Inc.

    Biorestorative Therapies Inc. • Address: 40 Markus Drive, Melville, NY 11747 Suite 1 • Phone: 631-760-8100 • Website: www.biorestorative.com 24

BioRestorative Therapies — Investor Presentation (January 2024) on 6ix